Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies

Karlijn A. Wouters, Leontien C.M. Kremer, Tracie L. Miller, Eugene H. Herman, Steven E. Lipshultz

Research output: Contribution to journalReview article

331 Scopus citations

Abstract

Over the last 40 years, great progress has been made in treating childhood and adult cancers. However, this progress has come at an unforeseen cost, in the form of emerging long-term effects of anthracycline treatment. A major complication of anthracycline therapy is its adverse cardiovascular effects. If these cardiac complications could be reduced or prevented, higher doses of anthracyclines could potentially be used, thereby further increasing cancer cure rates. Moreover, as the incidence of cardiac toxicity resulting in congestive heart failure or even heart transplantation dropped, the quality and extent of life for cancer survivors would improve. We review the proposed mechanisms of action of anthracyclines and the consequences associated with anthracycline treatment in children and adults. We summarise the most promising current strategies to limit or prevent anthracycline-induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening.

Original languageEnglish (US)
Pages (from-to)561-578
Number of pages18
JournalBritish Journal of Haematology
Volume131
Issue number5
DOIs
StatePublished - Dec 1 2005

Keywords

  • Anthracyclines
  • Cancer
  • Cardioprotective agents
  • Myocardial damage
  • Prevention

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies'. Together they form a unique fingerprint.

  • Cite this